Chris de Jonghe
Director/Miembro de la Junta en FORMAC Pharmaceuticals NV .
Perfil
Chris de Jonghe is the founder of Multiplicom NV, which was founded in 2011.
She is currently the Director at MyCartis NV, Non-Executive Director at FORMAC Pharmaceuticals NV, Director at Vesalius Biocapital I SA SICAR, Director at Vesalius Biocapital II SA SICAR, Valorization director at Oncode BV since 2020, Head of Life Sciences & Care at Participatiemaatschappij Vlaanderen NV since 2013, and a Member at FlandersBio vzw.
In the past, she has worked as a Director at reMYND NV, Independent Non-Executive Director at Celyad Oncology SA from 2015 to 2017, Non-Executive Director at Amakem NV, Director at Biotalys NV, Non-Executive Director at eSATURNUS NV, and Director at Confo Therapeutics NV.
Dr. de Jonghe holds graduate and doctorate degrees from the University of Antwerp.
Cargos activos de Chris de Jonghe
| Empresas | Cargo | Inicio |
|---|---|---|
Participatiemaatschappij Vlaanderen NV
 Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Inversor de Capital Privado | 01/12/2012 |
FORMAC Pharmaceuticals NV
 FORMAC Pharmaceuticals NV Pharmaceuticals: GenericHealth Technology FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium. | Director/Miembro de la Junta | - |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Corporate Officer/Principal | - |
Vesalius Biocapital I SA SICAR
 Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Director/Miembro de la Junta | - |
Vesalius Biocapital II SA SICAR
 Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Director/Miembro de la Junta | - |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Director/Miembro de la Junta | - |
Oncode BV
 Oncode BV Investment ManagersFinance Oncode BV is a venture capital firm, a subsidiary of Oncode Institute, founded in 2018. Oncode BV is headquartered in Utrecht. | Corporate Officer/Principal | 01/05/2020 |
Antiguos cargos conocidos de Chris de Jonghe.
| Empresas | Cargo | Fin |
|---|---|---|
| CELYAD ONCOLOGY SA | Director/Miembro de la Junta | 05/05/2017 |
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Director/Miembro de la Junta | - |
| ░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | - |
| ░░░░░░░░░░░ ░░ | ░░░░░░░░ | - |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | - |
Formación de Chris de Jonghe.
| University of Antwerp | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| BIOTALYS NV | Process Industries |
| Empresas privadas | 12 |
|---|---|
Participatiemaatschappij Vlaanderen NV
Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Finance |
MyCartis NV
MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
FORMAC Pharmaceuticals NV
FORMAC Pharmaceuticals NV Pharmaceuticals: GenericHealth Technology FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium. | Health Technology |
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
Vesalius Biocapital I SA SICAR
Vesalius Biocapital I SA SICAR Investment ManagersFinance Vesalius Biocapital I SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Commercial Services |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Health Services |
Multiplicom NV
 Multiplicom NV Medical SpecialtiesHealth Technology Multiplicom NV develops, manufactures, and commercializes molecular diagnostics solutions. It specializes in pathology laboratories, next generation sequencing, multiplex amplification of specific targets for resequencing, genetics, assay kits, clinical laboratories, and personalized medicine. The company was founded by Chris De Jonghe in 2011 and is headquartered in Niel, Belgium. | Health Technology |
Vesalius Biocapital II SA SICAR
Vesalius Biocapital II SA SICAR Investment ManagersFinance Vesalius Biocapital II SA Sicar focuses on healthcare companies that are in the early stage or that are corporate spin-offs. The fund invests mainly in Europe with a more precise focus on the Benelux countries. Vesalius invests up to EUR 10 million and may invest a few hundred thousand euros in a seed project. | Finance |
eSATURNUS NV
 eSATURNUS NV BiotechnologyHealth Technology eSATURNUS NV provides healthcare services for hospitals, doctors, nursing staff, and patients. The company was founded by Thomas Koninckx and Bob Koninckx on April 6, 2007 and is headquartered in Leuven, Belgium. | Health Technology |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Oncode BV
Oncode BV Investment ManagersFinance Oncode BV is a venture capital firm, a subsidiary of Oncode Institute, founded in 2018. Oncode BV is headquartered in Utrecht. | Finance |
- Bolsa de valores
- Insiders
- Chris de Jonghe
